Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.66 |
| ▸ | THRB | P10828 | 1/20 | 0.66 |
| ▸ | TSHR | P16473 | 1/20 | 0.66 |
| ▸ | ATM | Q13315 | 1/20 | 0.62 |
| ▸ | CA1 | P00915 | 5/20 | 0.59 |
| ▸ | CA2 | P00918 | 5/20 | 0.59 |
| ▸ | CA9 | Q16790 | 5/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.57 |
| ▸ | CA12 | O43570 | 4/20 | 0.55 |
| ▸ | GLA | P06280 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7949201 | 0.84 | LMNA (0.68) | LMNAMAPK1ALDH1A1THRBTSHR | |
| SCHEMBL9711175 | 0.82 | MAPK1 (0.76) | LMNAMAPK1ALDH1A1THRBTSHR | |
| SCHEMBL28927348 | 0.82 | LMNA (0.76) | LMNAMAPK1ALDH1A1THRBTSHR | |
| Hydrochloric Acid SCHEMBL12004705 | 0.81 | LMNA (0.64) | LMNAMAPK1ALDH1A1THRBTSHR | |
| SCHEMBL681530 | 0.81 | LMNA (0.73) | LMNAMAPK1ALDH1A1THRBTSHR | |
| Metronidazole SCHEMBL28233371 | 0.80 | LMNA (0.94) | LMNAMAPK1ALDH1A1THRBTSHR | |
| Metronidazole SCHEMBL6911811 | 0.80 | LMNA (0.94) | LMNAMAPK1ALDH1A1THRBTSHR | |
| SCHEMBL3466681 | 0.79 | LMNA (0.62) | LMNAMAPK1ALDH1A1THRBTSHR | |
| Metronidazole SCHEMBL5313560 | 0.79 | LMNA (1.00) | LMNAMAPK1ALDH1A1THRBTSHR | |
| SCHEMBL4091924 | 0.79 | LMNA (0.71) | LMNAMAPK1ALDH1A1THRBTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116283925-A | Iminophenazine derivative coupling molecule for treating bacterial infection and application thereof | 丹诺医药(苏州）有限公司 | 2023-06-23 | — | — | CN | claimed |
| EP-2588461-B1 | METRONIDAZOLE ESTERS FOR TREATING ROSACEA | GALDERMA RES & DEV (FR) | 2014-11-05 | — | — | EP | claimed |
| EP-2588462-B1 | METRONIDAZOLE ESTERS FOR TREATING ROSACEA | GALDERMA RES & DEV (FR) | 2014-08-13 | — | — | EP | claimed |
| EP-2588463-B1 | METRONIDAZOLE ESTERS FOR TREATING ROSACEA | GALDERMA RES & DEV (FR) | 2014-08-13 | — | — | EP | claimed |
| US-8802710-B2 | Metronidazole esters for treating rosacea | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2014-08-12 | — | — | US | claimed |
| US-20130217740-A1 | METRONIDAZOLE ESTERS FOR TREATING ROSACEA | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2013-08-22 | — | — | US | claimed |
| US-20130158090-A1 | METRONIDAZOLE ESTERS FOR TREATING ROSACEA | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2013-06-20 | — | — | US | claimed |
| EP-2588462-A1 | METRONIDAZOLE ESTERS FOR TREATING ROSACEA | Galderma Research & Development (FR) | 2013-05-08 | — | — | EP | claimed |
| EP-2588463-A1 | METRONIDAZOLE ESTERS FOR TREATING ROSACEA | Galderma Research & Development (FR) | 2013-05-08 | — | — | EP | claimed |
| WO-2012001053-A1 | METRONIDAZOLE ESTERS FOR TREATING ROSACEA | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2012-01-05 | — | — | WO | claimed |
| WO-2012001054-A1 | METRONIDAZOLE ESTERS FOR TREATING ROSACEA | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2012-01-05 | — | — | WO | claimed |
| US-7608724-B2 | 2-(2-Methyl-5-nitro-1H-imidazol-1-yl)ethyl 4-[(aminocarbonothioyl)amino]-4-oxobutanoate;potententiation; anaerobic/ aerobic microoraganisms; grampositive,gramnegative bacteria; Campylobacter; respiratory system disorders; paraciticides; nontoxic; enzymers/hydrolases/;enzyme inhibitors | EMS S.A. (BR) | 2009-10-27 | — | — | US | claimed |
| EP-1685114-B1 | ANTIBACTERIAL AND/OR ANTIPROTOZOAL NITROIMIDAZOLE DERIVATIVE COMPOUNDS WITH UREASE INHIBITOR ACTIVITY, PROCESS FOR PREPARING THESE COMPOUNDS AND USE IN PHARMACEUTICAL COMPOSITIONS AND MEDICINES. | EMS SA (BR) | 2008-10-15 | — | — | EP | claimed |
| US-20070072929-A1 | Antibacterial and/or antiprotozoal nitromidazole derivative compounds with urease inhibitor activity, process for preparing these compounds and use in pharmaceutical compositions and medicines | EMS S.A. (BR) | 2007-03-29 | — | — | US | claimed |
| EP-1685114-A2 | ANTIBACTERIAL AND/OR ANTIPROTOZOAL NITROIMIDAZOLE DERIVATIVE COMPOUNDS WITH UREASE INHIBITOR ACTIVITY, PROCESS FOR PREPARING THESE COMPOUNDS AND USE IN PHARMACEUTICAL COMPOSITIONS AND MEDICINES. | EMS S.A. (BR) | 2006-08-02 | — | — | EP | claimed |
| WO-2005041853-A2 | ANTIBACTERIAL AND/OR ANTIPROTOZOAL NITROIMIDAZOLE DERIVATIVE COMPOUNDS WITH UREASE INHIBITOR ACTIVITY, PROCESS FOR PREPARING THESE COMPOUNDS AND USE IN PHARMACEUTICAL COMPOSITIONS AND MEDICINES. | EMS S.A. (BR) | 2005-05-12 | — | — | WO | claimed |
| CN-1081637-C | Radiosensitizing diamines and their pharmaceutical preparations | UNIV FLORIDA STATE (US) | 2002-03-27 | — | — | CN | claimed |
| CN-116283925-A | Iminophenazine derivative coupling molecule for treating bacterial infection and application thereof | 丹诺医药(苏州）有限公司 | 2023-06-23 | — | — | CN | disclosed |
| EP-0315405-A1 | 4-phenyl-4-(N-(2-fluorophenyl)amido) piperidine derivatives | Ohmeda Pharmaceutical Products Division Inc. (US) | 1989-05-10 | — | — | EP | disclosed |
| US-4791121-A | ANALGESICS | THE BOC GROUP, INC. (US) | 1988-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072929-A1 | Antibacterial and/or antiprotozoal nitromidazole derivative compounds with urease inhibitor activity, process for preparing these compounds and use in pharmaceutical compositions and medicines | UMPS, PNP, UROD | LMNA 1783/4885MAPK1 2526/4885ALDH1A1 2614/4885 |
| US-20130158090-A1 | METRONIDAZOLE ESTERS FOR TREATING ROSACEA | CYP2C19, CYP2E1, MDH2 | LMNA 3163/4885MAPK1 4296/4885ALDH1A1 48/4885 |
| US-20130217740-A1 | METRONIDAZOLE ESTERS FOR TREATING ROSACEA | CYP2C19, MDH2, CYP2E1 | LMNA 3374/4885MAPK1 4221/4885ALDH1A1 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.